You searched for "epithelial"
Do steroids prevent progression to proliferative diabetic retinopathy (PDR)?
There is continuing debate on the merits of pan-retinal photocoagulation (PRP) for severe pre-proliferative and proliferative DR versus the newer therapies that inhibit vascular endothelial growth factor (VEGF). This has been hotly debated [1] following the publication of findings from...Can OCT predict Alzheimer’s disease?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Can OCT predict Alzheimer’s disease? In 1986 Hinton et al. demonstrated evidence of optic nerve degeneration...The results of the last survey Dec20
The responses to the first question in this survey demonstrate the need for it and the significant variation in practice we see in even relatively simple management decisions. Patients are seen regularly with occludable drainage angles and listed for YAG...Running a high-volume nurse led intravitreal service using the Sp.eye device – the Stanley Eye Unit experience
Introduction The vast majority of ophthalmology units utilise allied healthcare professionals (AHPs) to deliver intravitreal injections (IVIs). The Royal College of Ophthalmologists issued a statement 10 years ago advocating the use of non-medical practitioners performing IVIs [1]. The main benefit...A case of ‘60-day glaucoma’
Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...Initiatives in macular service provision
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...Strategies for managing neovascular AMD and DMO in routine clinical care
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...
